ReviewInternational journal of molecular sciences2022
Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CDR-Informed Graph Neural Network for Plasma Metabolomics in Lung Cancer and Pulmonary Neuroendocrine Neoplasms.International journal of molecular sciences · 2026Article
- Integration of blood protein-metabolic profiles via machine learning to enable the accurate early detection of non-small cell lung cancer.Respiratory research · 2026Article
- Extracellular Matrix Microstructures Directly Regulate Glutathione Bioavailability in Human Hepatocytes.Biomacromolecules · 2025Article
- M-GNN: A Graph Neural Network Framework for Lung Cancer Detection Using Metabolomics and Heterogeneous Graph Modeling.International journal of molecular sciences · 2025Article
- Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status.International journal of molecular sciences · 2024Article
- Identification of a Novel Biomarker Panel for Breast Cancer Screening.International journal of molecular sciences · 2024Article
- Application of omics technologies in studies on antitumor effects of Traditional Chinese Medicine.Chinese medicine · 2024Review
- Advances in early detection of non-small cell lung cancer: A comprehensive review.Cancer medicine · 2024Review
- Metabolomics-based search for lung cancer markers among patients with different smoking status.Scientific reports · 2024Article
- [Research Progress on Tumor Metabolic Biomarkers in Liquid Biopsy of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection.Journal of cancer research and clinical oncology · 2023Article
- Construction of the XGBoost model for early lung cancer prediction based on metabolic indices.BMC medical informatics and decision making · 2023Article
- The use of biomarkers in the diagnosis of lung cancer.La Tunisie medicale · 2023Article
- Biomarkers for Early Detection of Cancer: Molecular Aspects.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The five-year survival rate of lung cancer patients is very low, mainly because most newly diagnosed patients present with locally advanced or metastatic disease. Therefore, early diagnosis is key to the successful treatment and management of lung cancer. Unfortunately, early detection methods of lung cancer are not ideal. In this brief review, we described early detection methods such as chest X-rays followed by bronchoscopy, sputum analysis followed by cytological analysis, and low-dose computed tomography (LDCT). In addition, we discussed the potential of metabolomic fingerprinting, compared to that of other biomarkers, including molecular targets, as a low-cost, high-throughput blood-based test that is both feasible and affordable for early-stage lung cancer screening of at-risk populations. Accordingly, we proposed a paradigm shift to metabolomics as an alternative to molecular and proteomic-based markers in lung cancer screening, which will enable blood-based routine testing and be accessible to those patients at the highest risk for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.